# KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD

Study · id `cardio:ct-nct02268994` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02268994](<https://clinicaltrials.gov/study/NCT02268994>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02268994

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 234 participants.

## Technical summary

Registry record NCT02268994. Randomized; quadruple masking; primary purpose treatment. Start 2014-10 (registry gives no type); primary completion 2016-01 (actual). Results posted on 2018-02-22.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 234 participants (enrolled count; ClinicalTrials.gov record NCT02268994, source copy `cardio:ctgov-nct02268994-2018-03-22`, retrieved 2026-10-26)
- Start date: 2014-10 (registry gives no type) (ClinicalTrials.gov record NCT02268994, source copy `cardio:ctgov-nct02268994-2018-03-22`, retrieved 2026-10-26)
- Primary completion: 2016-01 (actual) (ClinicalTrials.gov record NCT02268994, source copy `cardio:ctgov-nct02268994-2018-03-22`, retrieved 2026-10-26)
- Completion: 2016-01 (actual) (ClinicalTrials.gov record NCT02268994, source copy `cardio:ctgov-nct02268994-2018-03-22`, retrieved 2026-10-26)
- Results first posted: 2018-02-22 (ClinicalTrials.gov record NCT02268994, source copy `cardio:ctgov-nct02268994-2018-03-22`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02268994, source copy `cardio:ctgov-nct02268994-2018-03-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02268994-2018-03-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
- Condition: Anemia of Chronic Kidney Disease
- Intervention (Drug): ferric citrate
- Intervention (Drug): Placebo
- Lead sponsor: Keryx Biopharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Keryx Biopharmaceuticals (`cardio:org-keryx-biopharmaceuticals`)

## Provenance

Content hash: e6ced8f970594d0b24f51325eacc34cc157f9d36059fb04ede98b3fb5cd12688
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
